B. Jin

发表

Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

J. Wagner, R. Krishna, A. Maes, 2011, Journal of clinical pharmacology.

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

L. V. Van Bortel, A. Bergman, J. Wagner, 2009, British journal of clinical pharmacology.

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

J. Chodakewitz, J. Wagner, R. Krishna, 2009, British journal of clinical pharmacology.

Effect of Low‐, Moderate‐, and High‐Fat Meals on Raltegravir Pharmacokinetics

J. Chodakewitz, J. Wagner, D. Brainard, 2011, Journal of clinical pharmacology.

Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single‐Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects

T. Marbury, D. Panebianco, L. Caro, 2011, Journal of clinical pharmacology.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, J. Wagner, B. Nguyen, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Pharmacokinetic Comparison of Adult and Paediatric Formulations of Raltegravir in Healthy Adults

M. Rizk, J. Wagner, Elizabeth G. Rhee, 2014, Antiviral therapy.

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

J. Chodakewitz, J. Wagner, T. Marbury, 2009, Antimicrobial Agents and Chemotherapy.

Effect of Aprepitant 40 mg on Cyto - chrome P-450 2C9 Activity: A Random- ized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Healthy Young Adults

D. Panebianco, M. Murphy, Judith K. Evans, 2009 .

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

John A Wagner, Rajesh Krishna, Arthur J Bergman, 2007, The Lancet.

Effect of Raltegravir on the Pharmacokinetics of Methadone

J. Wagner, W. Hanley, M. Iwamoto, 2010, Journal of clinical pharmacology.

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Anup Majumdar, A. Bergman, K. Lasseter, 2007, Journal of clinical pharmacology.

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects

T. Marbury, D. Panebianco, M. Murphy, 2009, Anesthesia and analgesia.

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

J. Wagner, J. Stone, W. Hanley, 2011, British journal of clinical pharmacology.